People in Brief | Alliance Pharma, Pfizer, BAH

People in Brief | Alliance Pharma, Pfizer, BAH
Bayer Vital's Tobias Boldt has been elected one of three deputy chairmen of the German Medicines Manufacturers' Association, the BAH

1 July 2019 - Deborah Wilkes

Alliance Pharma, Pfizer and the German Medicines Manufacturers' Association, the BAH, have all recently announced people changes.

Dawson leaves Alliance after 23 years

Alliance Pharma has announced that John Dawson – its founder and former chief executive officer – has left the company after 23 years.

Dawson, who founded Alliance Pharma in 1996, stepped down as chief executive officer on 1 May 2018 but remained on the Board as a non-executive director.

He was replaced as chief executive officer by the company's deputy chief executive officer, Peter Butterfield (click here to read the News story).

Commenting on his departure from Alliance Pharma, Dawson said he would soon be participating in the 2019/20 Clipper Round the World Yacht Race.

Gottlieb joins Pfizer's Board

Pfizer has elected Scott Gottlieb – former commissioner of the US Food and Drug Administration (FDA) – to its Board of Directors. Gottlieb has also been appointed to the company's Regulatory and Compliance Committee and its Science and Technology Committee.

Commenting on Gottlieb's appointment, Albert Bourla, Pfizer's chief executive officer, said: "Through his work as a physician and his time at the FDA, Scott has continually demonstrated an understanding of both patients' needs and the rapidly-changing dynamics of biopharmaceutical research and development."

Gottlieb resigned as FDA commissioner in March 2019, just two years after he was appointed to the post (click here to read the News story).

Soon afterwards, he rejoined venture capital firm New Enterprise Associates (NEA) as a special partner on the firm's healthcare investment team. Prior to joining the FDA, Gottlieb was a venture partner at NEA from 2007 until 2017.

BAH elects deputy chairman

The German Medicines Manufacturers' Association, the BAH, has elected Bayer's Tobias Boldt as one of three deputy chairmen.

Boldt is head of Consumer Health at Bayer Vital and has been a member of the BAH's Board of Directors since 2018.

He joins two other deputy chairmen, Philipp Huwe of AbbVie and Traugott Ullrich of Dr Willmar Schwabe. The board's chairman is Jörg Wieczorek of Hermes Arzneimittel.

The BAH recently appointed Hubertus Cranz – former director general of the Association of the European Self-Medication Industry, the AESGP – as its director general (click here to read the News story).

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE

Click tags below for more information on topics:

Bayer Consumer Health FDA Pfizer

Back to Industry News

Share this page: